Patents by Inventor Bashar KHIATAH

Bashar KHIATAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable dithizone solutions and formulations and methods for their use
    Patent number: 11579051
    Abstract: An optimized Dipheylthiocarbazone or Dithizone (DTZ) solution was developed with preferred physical and chemical properties to characterize human islets and insulin producing cells differentiated from embryonic stem cells. Application of the newly formulated iDTZ (i stands for islet) over a range of temperatures, time intervals and cell and tissue types found to be robust for identifying these cells. The iDTZ, through high transition zinc binding, concentrated in insulin producing cells could also be used to delineate zinc levels in tissue and liquid samples.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: February 14, 2023
    Assignee: CITY OF HOPE
    Inventors: Ismail H. Al-Abdullah, Meirigeng Qi, Bashar Khiatah, Luis Valiente
  • METHODS OF STROMAL CELL EXPANSION, USES AND MATERIALS RELATED THERETO
    Publication number: 20210130789
    Abstract: Disclosed herein are methods for expanding and potentiating intra-pancreatic tissue-derived mesenchymal stromal/stem cells in the presence of TNF-?, DMOG, or both, to obtain IPTD-MSCs having enhanced pro-angiogenic and/or anti-inflammatory properties. Also disclosed are therapeutic applications of these IPTD-MSCs.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 6, 2021
    Applicant: CITY OF HOPE
    Inventors: Ismail H. AL-ABDULLAH, Meirigeng QI, Hsun Terasa KU, Bashar KHIATAH
  • STABLE DITHIZONE SOLUTIONS AND FORMULATIONS AND METHODS FOR THEIR USE
    Publication number: 20200319065
    Abstract: An optimized Dipheylthiocarbazone or Dithizone (DTZ) solution was developed with preferred physical and chemical properties to characterize human islets and insulin producing cells differentiated from embryonic stem cells. Application of the newly formulated iDTZ (i stands for islet) over a range of temperatures, time intervals and cell and tissue types found to be robust for identifying these cells. The iDTZ, through high transition zinc binding, concentrated in insulin producing cells could also be used to delineate zinc levels in tissue and liquid samples.
    Type: Application
    Filed: March 11, 2020
    Publication date: October 8, 2020
    Applicant: CITY OF HOPE
    Inventors: Ismail H. AL-ABDULLAH, Meirigeng QI, Bashar KHIATAH, Luis VALIENTE